Which has preferable earnings & valuation, IQV or BRKR?

IQVIA has higher revenue and earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IQVIA $16.31B 1.86 $1.36B $8.07 22.57 Bruker $3.44B 2.78 -$8.60M -$0.24 N/A

Is IQV or BRKR more profitable?

IQVIA has a net margin of 8.33% compared to Bruker's net margin of -0.65%. IQVIA's return on equity of 30.50% beat Bruker's return on equity. Company Net Margins Return on Equity Return on Assets IQVIA 8.33% 30.50% 6.53% Bruker -0.65% 11.60% 4.25%

Does the media refer more to IQV or BRKR?

In the previous week, IQVIA and IQVIA both had 8 articles in the media. Bruker's average media sentiment score of 0.54 beat IQVIA's score of 0.10 indicating that Bruker is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IQVIA 0 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Bruker 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, IQV or ICLR?

IQVIA has higher revenue and earnings than Icon. IQVIA is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IQVIA $16.31B 1.86 $1.36B $8.07 22.57 Icon $8.25B 1.41 $229.34M $6.16 23.40

Is IQV or ICLR more profitable?

IQVIA has a net margin of 8.33% compared to Icon's net margin of 5.98%. IQVIA's return on equity of 30.50% beat Icon's return on equity. Company Net Margins Return on Equity Return on Assets IQVIA 8.33% 30.50% 6.53% Icon 5.98% 9.50% 5.40%

Does the media prefer IQV or ICLR?

In the previous week, Icon had 10 more articles in the media than IQVIA. MarketBeat recorded 18 mentions for Icon and 8 mentions for IQVIA. IQVIA's average media sentiment score of 0.10 beat Icon's score of 0.09 indicating that IQVIA is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IQVIA 0 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Icon 2 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, IQV or MEDP?

IQVIA has higher revenue and earnings than Medpace. IQVIA is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IQVIA $16.31B 1.86 $1.36B $8.07 22.57 Medpace $2.53B 5.09 $451.12M $15.91 28.34

Is IQV or MEDP more profitable?

Medpace has a net margin of 17.19% compared to IQVIA's net margin of 8.33%. Medpace's return on equity of 120.89% beat IQVIA's return on equity. Company Net Margins Return on Equity Return on Assets IQVIA 8.33% 30.50% 6.53% Medpace 17.19% 120.89% 24.79%

Does the media prefer IQV or MEDP?

In the previous week, Medpace had 26 more articles in the media than IQVIA. MarketBeat recorded 34 mentions for Medpace and 8 mentions for IQVIA. Medpace's average media sentiment score of 0.27 beat IQVIA's score of 0.10 indicating that Medpace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IQVIA 0 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Medpace 7 Very Positive mention(s) 1 Positive mention(s) 24 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, IQV or TECH?

IQVIA has higher revenue and earnings than Bio-Techne. IQVIA is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IQVIA $16.31B 1.86 $1.36B $8.07 22.57 Bio-Techne $1.22B 6.53 $73.40M $0.69 73.70

Is IQV or TECH more profitable?

Bio-Techne has a net margin of 9.05% compared to IQVIA's net margin of 8.33%. IQVIA's return on equity of 30.50% beat Bio-Techne's return on equity. Company Net Margins Return on Equity Return on Assets IQVIA 8.33% 30.50% 6.53% Bio-Techne 9.05% 13.57% 10.66%

Does the media prefer A or IQV?

In the previous week, Agilent Technologies had 33 more articles in the media than IQVIA. MarketBeat recorded 41 mentions for Agilent Technologies and 8 mentions for IQVIA. Agilent Technologies' average media sentiment score of 0.77 beat IQVIA's score of 0.10 indicating that Agilent Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agilent Technologies 16 Very Positive mention(s) 6 Positive mention(s) 11 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive IQVIA 0 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

IQVIA (IQV) Competitors

$182.12 +1.48 (+0.82%)

Closing price 03:58 PM Eastern

Extended Trading

$177.02 -5.10 (-2.80%)

As of 07:46 PM Eastern

Compare

IQV vs. BRKR, ICLR, MEDP, TECH, and A

Should you buy IQVIA stock or one of its competitors? MarketBeat compares IQVIA with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with IQVIA include Bruker (BRKR), Icon (ICLR), Medpace (MEDP), Bio-Techne (TECH), and Agilent Technologies (A).

How does IQVIA compare to Bruker?

IQVIA (NYSE:IQV) and Bruker (NASDAQ:BRKR) are related companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

IQVIA has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market. Comparatively, Bruker has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market.

In the previous week, IQVIA and IQVIA both had 8 articles in the media. Bruker's average media sentiment score of 0.54 beat IQVIA's score of 0.10 indicating that Bruker is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IQVIA	0 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bruker	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

89.6% of IQVIA shares are held by institutional investors. Comparatively, 79.5% of Bruker shares are held by institutional investors. 1.7% of IQVIA shares are held by insiders. Comparatively, 27.2% of Bruker shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

IQVIA currently has a consensus price target of $224.13, indicating a potential upside of 23.06%. Bruker has a consensus price target of $50.54, indicating a potential downside of 19.40%. Given IQVIA's stronger consensus rating and higher probable upside, equities analysts clearly believe IQVIA is more favorable than Bruker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.00
Bruker	2 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.40

IQVIA has higher revenue and earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$16.31B	1.86	$1.36B	$8.07	22.57
Bruker	$3.44B	2.78	-$8.60M	-$0.24	N/A

IQVIA has a net margin of 8.33% compared to Bruker's net margin of -0.65%. IQVIA's return on equity of 30.50% beat Bruker's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQVIA	8.33%	30.50%	6.53%
Bruker	-0.65%	11.60%	4.25%

Summary

IQVIA beats Bruker on 12 of the 16 factors compared between the two stocks.

How does IQVIA compare to Icon?

IQVIA (NYSE:IQV) and Icon (NASDAQ:ICLR) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

89.6% of IQVIA shares are held by institutional investors. Comparatively, 95.6% of Icon shares are held by institutional investors. 1.7% of IQVIA shares are held by company insiders. Comparatively, 44.0% of Icon shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

IQVIA has a net margin of 8.33% compared to Icon's net margin of 5.98%. IQVIA's return on equity of 30.50% beat Icon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQVIA	8.33%	30.50%	6.53%
Icon	5.98%	9.50%	5.40%

In the previous week, Icon had 10 more articles in the media than IQVIA. MarketBeat recorded 18 mentions for Icon and 8 mentions for IQVIA. IQVIA's average media sentiment score of 0.10 beat Icon's score of 0.09 indicating that IQVIA is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IQVIA	0 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Icon	2 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

IQVIA has higher revenue and earnings than Icon. IQVIA is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$16.31B	1.86	$1.36B	$8.07	22.57
Icon	$8.25B	1.41	$229.34M	$6.16	23.40

IQVIA presently has a consensus price target of $224.13, indicating a potential upside of 23.06%. Icon has a consensus price target of $156.44, indicating a potential upside of 8.54%. Given IQVIA's stronger consensus rating and higher probable upside, research analysts clearly believe IQVIA is more favorable than Icon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.00
Icon	2 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.33

IQVIA has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market. Comparatively, Icon has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market.

Summary

IQVIA beats Icon on 12 of the 17 factors compared between the two stocks.

How does IQVIA compare to Medpace?

IQVIA (NYSE:IQV) and Medpace (NASDAQ:MEDP) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Medpace has a net margin of 17.19% compared to IQVIA's net margin of 8.33%. Medpace's return on equity of 120.89% beat IQVIA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQVIA	8.33%	30.50%	6.53%
Medpace	17.19%	120.89%	24.79%

In the previous week, Medpace had 26 more articles in the media than IQVIA. MarketBeat recorded 34 mentions for Medpace and 8 mentions for IQVIA. Medpace's average media sentiment score of 0.27 beat IQVIA's score of 0.10 indicating that Medpace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IQVIA	0 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medpace	7 Very Positive mention(s)	1 Positive mention(s)	24 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

IQVIA has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market. Comparatively, Medpace has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market.

IQVIA has higher revenue and earnings than Medpace. IQVIA is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$16.31B	1.86	$1.36B	$8.07	22.57
Medpace	$2.53B	5.09	$451.12M	$15.91	28.34

89.6% of IQVIA shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 1.7% of IQVIA shares are owned by insiders. Comparatively, 20.5% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

IQVIA currently has a consensus price target of $224.13, suggesting a potential upside of 23.06%. Medpace has a consensus price target of $467.08, suggesting a potential upside of 3.61%. Given IQVIA's stronger consensus rating and higher probable upside, analysts clearly believe IQVIA is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.00
Medpace	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Medpace beats IQVIA on 9 of the 17 factors compared between the two stocks.

How does IQVIA compare to Bio-Techne?

IQVIA (NYSE:IQV) and Bio-Techne (NASDAQ:TECH) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

IQVIA presently has a consensus target price of $224.13, suggesting a potential upside of 23.06%. Bio-Techne has a consensus target price of $65.92, suggesting a potential upside of 29.64%. Given Bio-Techne's higher possible upside, analysts plainly believe Bio-Techne is more favorable than IQVIA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.00
Bio-Techne	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.79

IQVIA has higher revenue and earnings than Bio-Techne. IQVIA is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$16.31B	1.86	$1.36B	$8.07	22.57
Bio-Techne	$1.22B	6.53	$73.40M	$0.69	73.70

IQVIA has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market.

Bio-Techne has a net margin of 9.05% compared to IQVIA's net margin of 8.33%. IQVIA's return on equity of 30.50% beat Bio-Techne's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQVIA	8.33%	30.50%	6.53%
Bio-Techne	9.05%	13.57%	10.66%

In the previous week, IQVIA had 7 more articles in the media than Bio-Techne. MarketBeat recorded 8 mentions for IQVIA and 1 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 1.89 beat IQVIA's score of 0.10 indicating that Bio-Techne is being referred to more favorably in the news media.

Company	Overall Sentiment
IQVIA	Neutral
Bio-Techne	Very Positive

89.6% of IQVIA shares are held by institutional investors. Comparatively, 99.0% of Bio-Techne shares are held by institutional investors. 1.7% of IQVIA shares are held by insiders. Comparatively, 1.3% of Bio-Techne shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

IQVIA beats Bio-Techne on 9 of the 17 factors compared between the two stocks.

How does IQVIA compare to Agilent Technologies?

Agilent Technologies (NYSE:A) and IQVIA (NYSE:IQV) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

89.6% of IQVIA shares are owned by institutional investors. 1.7% of IQVIA shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Agilent Technologies has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, IQVIA has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market.

In the previous week, Agilent Technologies had 33 more articles in the media than IQVIA. MarketBeat recorded 41 mentions for Agilent Technologies and 8 mentions for IQVIA. Agilent Technologies' average media sentiment score of 0.77 beat IQVIA's score of 0.10 indicating that Agilent Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agilent Technologies	16 Very Positive mention(s)	6 Positive mention(s)	11 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
IQVIA	0 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Agilent Technologies has a net margin of 19.55% compared to IQVIA's net margin of 8.33%. IQVIA's return on equity of 30.50% beat Agilent Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agilent Technologies	19.55%	24.33%	12.99%
IQVIA	8.33%	30.50%	6.53%

IQVIA has higher revenue and earnings than Agilent Technologies. IQVIA is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agilent Technologies	$6.95B	5.61	$1.30B	$4.98	27.71
IQVIA	$16.31B	1.86	$1.36B	$8.07	22.57

Agilent Technologies presently has a consensus target price of $161.71, suggesting a potential upside of 17.18%. IQVIA has a consensus target price of $224.13, suggesting a potential upside of 23.06%. Given IQVIA's stronger consensus rating and higher possible upside, analysts plainly believe IQVIA is more favorable than Agilent Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agilent Technologies	0 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.94
IQVIA	0 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

IQVIA beats Agilent Technologies on 9 of the 16 factors compared between the two stocks.

Get IQVIA News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IQV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IQV vs. The Competition

Export

Metric	IQVIA	MED INSTRUMENTS Industry	Medical Sector	NYSE Exchange
Market Cap	$30.15B	$7.04B	$6.45B	$23.08B
Dividend Yield	N/A	1.21%	2.69%	4.09%
P/E Ratio	22.57	45.06	22.30	31.02
Price / Sales	1.86	86.79	581.44	14.81
Price / Cash	10.11	24.40	42.31	24.78
Price / Book	4.68	7.15	9.84	4.67
Net Income	$1.36B	$159.22M	$3.57B	$1.07B
7 Day Performance	9.73%	0.91%	-1.16%	-0.67%
1 Month Performance	15.47%	3.99%	3.85%	0.22%
1 Year Performance	27.59%	1.56%	27.40%	25.44%

IQVIA Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IQV IQVIA	4.3243 of 5 stars	$182.12 +0.8%	$224.13 +23.1%	+29.8%	$30.15B	$16.31B	22.57	93,000	Analyst Forecast
BRKR Bruker	1.709 of 5 stars	$58.44 -0.8%	$50.54 -13.5%	+56.0%	$8.96B	$3.44B	N/A	11,085	Analyst Forecast
ICLR Icon	2.6233 of 5 stars	$138.03 +1.4%	$156.44 +13.3%	+6.7%	$10.99B	$8.25B	22.41	41,900	Earnings Report Analyst Forecast
MEDP Medpace	2.1914 of 5 stars	$451.47 +1.0%	$467.08 +3.5%	+49.6%	$12.77B	$2.53B	28.38	6,200	Trending News Insider Trade
TECH Bio-Techne	4.1236 of 5 stars	$50.79 -1.7%	$65.92 +29.8%	+2.4%	$8.09B	$1.21B	73.61	3,100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:IQV) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IQVIA (IQV) Competitors